Trial Profile
To Investigate Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal vein occlusion
- Focus Therapeutic Use
- 24 Aug 2017 Status changed from active, no longer recruiting to completed.
- 02 Jul 2014 New trial record